Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingEarly Phase 1IIT An Exploratory Clinical Study of JV001 in the Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (Telomere Recapping to Restore Mitochondrial Biogenesis Study for Dilated Cardiomyopathy)
The aim of this study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing a modified telomerase protein (TERT), driven by cardiac troponin T promoter (AAV9-cTnT-modTERT), to 12 dilated cardiomyopathic patients.
100 Clinical Results associated with Shanghai Juvensis Therapeutics Biotechnology Company Limited
0 Patents (Medical) associated with Shanghai Juvensis Therapeutics Biotechnology Company Limited
100 Deals associated with Shanghai Juvensis Therapeutics Biotechnology Company Limited
100 Translational Medicine associated with Shanghai Juvensis Therapeutics Biotechnology Company Limited